[Weekly HOT Stocks] SK Biopharm Tops Individual Net Buying... IPO Price Hits 3.4 Times 'Big Hit'

On the Listing Day, Recorded 127,000 Won, 2.6 Times the IPO Price... Also Hit the Upper Limit on the 3rd, Closing at 165,000 Won

[Asia Economy Reporter Geum Bo-ryeong] SK Biopharm, regarded as the biggest IPO in this year's public offering market, was listed on the KOSPI on the 2nd. During the two trading days following the listing, SK Biopharm attracted the most attention in the securities market.

According to the Korea Exchange on the 5th, SK Biopharm closed at 165,000 KRW on the 3rd, up 29.92% (38,000 KRW) from the previous session.

On the listing day, the 2nd, SK Biopharm's opening price was 98,000 KRW, double the public offering price of 49,000 KRW. Considering that the opening price is usually formed at 90-200% of the public offering price, this was at the top end. Furthermore, the stock price immediately hit the upper limit, closing at 127,000 KRW on the listing day, about 2.6 times the public offering price. The closing price on the 3rd, which again hit the upper limit, was about 3.37 times the public offering price.

SK Biopharm's upward trend was anticipated. During the demand forecast for institutional investors held on the 17th and 18th of last month, the competition rate was 835.66 to 1. Subsequently, in the general subscription held on the 23rd and 24th, the subscription deposit amounted to 31.9889 trillion KRW, breaking the record set by Cheil Industries 6 years ago (30.0649 trillion KRW). The competition rate was 323.02 to 1. On online stock communities and elsewhere, comments like "Guaranteed jackpot if you buy," and "Put in money and get money" were posted.

Individual investors' interest continued even after the listing. According to the Korea Exchange, SK Biopharm ranked first among the stocks most net-purchased by individual investors during the week from the 29th of last month to the 3rd. Considering the listing on the 2nd, individual investors net-purchased SK Biopharm worth 98.4 billion KRW over two trading days.

SK Biopharm entered the KOSPI market capitalization ranking at 27th place on the listing day. The next day, it rose to 22nd place, higher than SK Innovation, LG, and Korea Electric Power Corporation. Kia Motors holds the 21st place, one rank above.

Seogeunhee, a researcher at Samsung Securities, explained the market's focus on SK Biopharm, saying, "From a fundamental perspective, the company holds two new drugs approved by the U.S. Food and Drug Administration (FDA), which confirms visible growth potential in the global market going forward, making it attractive. From a supply-demand perspective, the healthcare sector in KOSPI had only large-cap stocks like Celltrion and Samsung Biologics, so institutional investors see this as a positive opportunity to diversify their investment portfolios."

This content was produced with the assistance of AI translation services.